Bayer is improving people’s quality of life by preventing, alleviating and curing diseases. In 2018 we invested a total of €5.2 billion in research and development. This figure represents a sound platform to introduce further innovative products in expanding life science markets.
Bayer holds a worldwide leading position in its main therapeutic areas and our Pharmaceuticals portfolio focuses on:
General Medicine & Specialty Medicine - General Medicines consists of prescription products, especially for cardiology and women’s health, whilst Specialty Medicines covers the areas of haematology, neurology, oncology and ophthalmology.
Radiology - combines contrast-enhanced diagnostic imaging equipment and the necessary contrast agents into a single source for radiology and equipment support services.